Early temporary ART for HIV-infected infants prevents damage to immune system and delays need for life-long treatment

August 21, 2013

Giving antiretroviral therapy (ART) immediately after diagnosis for a limited period of time is more beneficial than postponing treatment in young infants infected with HIV, slowing progression of the disease and delaying the time to starting long-term ART, according to new research published in The Lancet.

"This important finding indicates we may be able to temporarily stop treatment and spare from some of the of continuous ART for a while, if we can monitor them carefully", explains Professor Mark Cotton from Stellenbosch University in South Africa, one of the study leaders.

"With ART coverage in children currently at just 28%, our findings highlight the urgency of increasing early (within the first 3 months of life) testing and treatment of HIV-infected infants."

Although giving early ART during infancy is beneficial and lifesaving, currently treatment must be taken for life and cumulative exposure increases the likelihood of drug-related toxicity and .

In 2005, the children with HIV early antiretroviral (CHER) trial, funded by the US National Institutes of Health, and with participation of the Medical Research Council Clinical Trial Unit in London, randomly assigned 377 HIV-infected infants (between 6 and 12 weeks of age) from South Africa to one of three regimens: immediate (PI)-based ART and continue for 40 weeks (ART-40W); immediate PI-based ART and continue for 96 weeks (ART-96W), with subsequent ; or defer PI-based ART until signs of illness or a (ART-Def; standard practice).

In 2007, interim results reported that after a median of 48 weeks, giving immediate PI-based ART reduced the risk of death and by 75% compared with deferring ART until signs of illness or a weakened immune system.

These findings led WHO to revise its treatment guidelines and recommend that ART be started immediately after HIV diagnosis in children under 1 year old rather than at a particular CD4 level.

Here, the investigators report the 5-year results of the completed CHER trial, showing that infants who began an immediate short course of ART could safely interrupt treatment and continue to do significantly better than infants in whom ART was deferred, and with less overall exposure to ART.

On average, infants who received deferred ART needed to begin taking life-long treatment 20 weeks after randomisation. Those given the immediate course of 40 weeks ART delayed the need for re-starting treatment by 33 weeks, and those who received the initial 96 week ART course delayed beginning long-term treatment by 70 weeks.

By the end of the trial, 24 infants (19%) given 40 weeks of early ART and 40 infants (32%) who received 96 weeks of initial ART were still well enough to remain off treatment.

What is more, despite a longer period of continuous ART, the deferred treatment group had a significantly higher number of deaths, clinical events, and admissions to hospital, and was more costly than time-limited ART.

According co-lead author Dr Avy Violari from the University of the Witwatersrand in South Africa, "Early treatment followed by a break is definitely better and more cost-effective than delaying starting infants on treatment. But we do not know if a longer initial period of treatment, or early continuous treatment, might be even better."

Writing in a linked Comment, Robert Colebunders from the University of Antwerp in Belgium and Victor Musiime from Makerere University College of Health Sciences in Kampala, Uganda, caution that little is known about the consequences of treatment interruptions and suggest that such a strategy may not be feasible in resource-poor settings such as Africa, where most children with HIV live, and where the availability of laboratories to monitor CD4 counts is limited.

However, they point out, "In the future, straightforward point-of-care tests…will probably become available for very early infant diagnosis. Together with new methods to monitor the infection, cessation of ART after a prolonged course of a highly effective treatment regimen could become an option…Indeed, if we were able to diagnose HIV infection in neonates very early and start ART shortly after birth, a prolonged period without ART, and perhaps even a functional cure in some children, can be expected."

Explore further: Studies show benefits of immediate antiretroviral treatment for HIV-infected infants

More information: www.thelancet.com/journals/lan … (13)61409-9/abstract

Related Stories

Studies show benefits of immediate antiretroviral treatment for HIV-infected infants

March 6, 2012
Results from two studies presented today at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle demonstrate the importance of identifying and treating HIV-infected infants within the first year ...

Study suggests early ART in recently HIV-infected patients preferable to delayed treatment

December 16, 2011
Among people recently infected with HIV, immediate antiretroviral therapy (ART) appears preferable to deferring treatment, according to a new study published in the Journal of Infectious Diseases and now available online. ...

Early antiretroviral treatment reduces viral reservoirs in HIV-infected teens

March 4, 2013
A study led by University of Massachusetts Medical School professor and immunologist Katherine Luzuriaga, MD, and Johns Hopkins Children's Center virologist Deborah Persaud, MD, highlights the long-term benefits of early ...

New HPTN 052 study results reveal additional benefits of early HIV treatment

July 26, 2012
Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes. Expanded analysis of HPTN 052 study data, presented today at ...

DNDi and Cipla advance development of pediatric 4-in-1 ARVs to fulfill new WHO guidelines

June 30, 2013
The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society (IAS) Conference, include new antiretroviral (ARV) therapy (ART) recommendations for HIV-infected children, ...

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.